DaVita Inc., a leading dialysis-provider, has downplayed the impact of GLP-1 drugs, such as Novo Nordisk A/S's Ozempic, after study results in kidney patients caused a significant drop in its stock value. The Denver-based company released a statement expressing eagerness to understand the results of the study, which revealed that Ozempic met an efficacy goal in treating kidney failure. However, DaVita believes that there may be limited application of these drugs to the overall patient population suffering from kidney disease.
GLP-1 drugs have been making waves across the healthcare industry and beyond. Earlier this week, kidney-care providers experienced a decline in their stock value after Novo announced that its diabetes drug showed surprisingly early effectiveness in a study involving patients with chronic kidney disease.
DaVita's shares, which saw a significant drop of almost 17% recently, managed to recover slightly with a 1.1% rise on Thursday. Similarly, Baxter International Inc., a company specializing in developing treatments for kidney disease, also saw a recovery of 1% after experiencing a drop of over 12% on the preceding day.
In response to the market reaction, Wells Fargo analysts stated that they believe the response to Novo's study has been an overreaction. They see GLP-1 drugs as having only a small impact on dialysis.
Patients with diabetes are at a higher risk of developing other health conditions, including kidney failure. However, full study results from Novo's research are not expected until 2024. DaVita believes that future trials and research will be required to determine whether the findings of the study can benefit a larger chronic kidney disease population beyond those specifically included in the trial.